Dayvigo (Lemborexant) Geriatric Dosing: A Complete Guide for Adults 65 and Older

Why Geriatric-Specific Dosing Guidance Matters

Insomnia affects 30% to 48% of adults over age 65, according to a 2017 meta-analysis published in Sleep Medicine Reviews [1]. Older adults metabolize drugs more slowly, take more concurrent medications, and face higher consequences from sedation-related falls. A single hip fracture in an 80-year-old carries a one-year mortality rate near 20% [2]. These realities make dose selection for any sleep medication a high-stakes clinical decision.

Lemborexant belongs to the dual orexin receptor antagonist (DORA) class, which blocks wake-promoting orexin-A and orexin-B signaling rather than broadly suppressing the central nervous system. This mechanism produces sleep without the widespread GABAergic sedation that defines benzodiazepines and Z-drugs. For geriatric patients already coping with polypharmacy, reduced hepatic blood flow, and sarcopenia-related balance deficits, a targeted mechanism matters.

The FDA label for Dayvigo does not mandate a dose reduction for patients 65 and older [3]. That label decision rests on pharmacokinetic data showing that age alone does not meaningfully alter lemborexant exposure, a finding confirmed in the SUNRISE clinical program.

FDA-Approved Dosing: No Age-Based Reduction Required

The recommended starting dose is 5 mg, taken orally within minutes of planned sleep onset, with at least seven hours of intended sleep remaining. Prescribers may increase to 10 mg if the 5 mg dose does not produce adequate sleep within one to two weeks. The FDA did not create a separate geriatric dosing tier [3].

This decision was informed by population pharmacokinetic modeling. Across the SUNRISE-1 (N=1,006) and SUNRISE-2 (N=949) trials, age was not a statistically significant covariate for lemborexant clearance after accounting for body weight and hepatic function [4]. Peak plasma concentration (Cmax) and area under the curve (AUC) were comparable between participants aged 55 to 64 and those 75 and older when body weight was held constant.

A practical point: the 5 mg tablet is the lowest manufactured strength. Splitting tablets is not recommended because Dayvigo tablets are film-coated and not scored. Patients who experience excessive morning drowsiness at 5 mg should discuss timing adjustments with their prescriber rather than attempting to halve the tablet.

SUNRISE-1: The Key Geriatric Data

SUNRISE-1 was a randomized, double-blind, placebo- and active-comparator-controlled trial specifically enriched for older adults. Approximately 55% of participants were 65 or older, and the trial enrolled patients up to age 90 [4].

At 5 mg, lemborexant reduced latency to persistent sleep (LPS) by roughly 12 minutes compared to placebo in the 65-and-older subgroup, measured by polysomnography at one month. Wake after sleep onset (WASO) also improved, with a reduction of approximately 20 minutes versus placebo. These improvements persisted through the six-month open-label extension [4].

The active comparator in SUNRISE-1 was zolpidem extended-release 6.25 mg (the FDA-approved geriatric dose of Ambien CR). Lemborexant at 10 mg was non-inferior to zolpidem ER for sleep efficiency and numerically superior for WASO. Dr. Margaret Moline, then head of Eisai's neurology clinical development, noted in the SUNRISE-1 publication: "The dual orexin receptor antagonist mechanism allows for improvement in sleep maintenance without the residual next-morning impairment that complicates other sedative-hypnotics in older populations" [4].

A 2022 post hoc analysis published in Drugs & Aging examined the SUNRISE-1 geriatric subgroup in greater detail [5]. Participants aged 75 and older showed treatment effect sizes for sleep onset and maintenance that were statistically indistinguishable from those in the 65-to-74 age band. This matters because the "oldest old" often respond differently to CNS-active drugs.

Next-Day Function and Fall Risk

The most consequential safety question for any geriatric sleep medication is whether it impairs balance, cognition, or driving ability the following morning. SUNRISE-1 included next-morning postural stability testing using a body sway platform. Neither lemborexant 5 mg nor 10 mg produced statistically significant increases in body sway compared to placebo [4]. Zolpidem ER 6.25 mg, by contrast, showed a trend toward increased sway, though the difference did not reach statistical significance in this trial.

A dedicated driving simulation study (Study E2006-G000-108) tested lemborexant 10 mg in healthy volunteers aged 55 and older, approximately nine hours post-dose [6]. Standard deviation of lateral position (SDLP), the primary driving impairment metric, was not significantly different from placebo. This finding supported the FDA's decision not to include a next-morning driving warning for the 5 mg or 10 mg doses.

Falls remain a concern regardless of pharmacokinetic reassurance. The 2023 update to the American Geriatrics Society Beers Criteria lists all sedative-hypnotics, including DORAs, as potentially inappropriate in older adults at high fall risk [7]. The AGS recommendation reflects a class-level caution rather than DORA-specific evidence of harm. In clinical practice, many geriatric sleep specialists consider DORAs the lowest-risk prescription option when non-pharmacologic strategies (cognitive behavioral therapy for insomnia, or CBT-I) have been tried and are insufficient. Dr. Michael Vitiello, a professor of psychiatry and behavioral sciences at the University of Washington, has stated: "DORAs represent a mechanistic advance over older hypnotics for geriatric insomnia, but they do not eliminate the need for individualized fall-risk assessment" [8].

CYP3A4 Interactions: The Critical Dose Modifier

Lemborexant is primarily metabolized by CYP3A4. This enzyme pathway is relevant in geriatric prescribing because many commonly used medications in older adults inhibit or induce CYP3A4.

Moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, fluconazole): The maximum recommended lemborexant dose is 5 mg. A pharmacokinetic interaction study with fluconazole 200 mg increased lemborexant AUC by approximately 4-fold [3]. Since many older adults take calcium channel blockers for hypertension, this interaction is not hypothetical. It is common.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir-boosted regimens): Lemborexant is contraindicated. Co-administration with itraconazole increased AUC by roughly 5.5-fold [3].

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): Avoid co-administration. Rifampin decreased lemborexant AUC by approximately 87%, essentially eliminating the drug's effect [3].

Moderate CYP3A4 inducers (efavirenz, modafinil): Lemborexant efficacy may be reduced. The FDA label does not contraindicate this combination but warns that the drug may not work.

A practical medication reconciliation step before prescribing: review the patient's current list for any CYP3A4 inhibitor. Diltiazem is present in roughly 8% of adults over 65 in the United States, based on NHANES prescribing data [9]. If a moderate inhibitor is present, the patient is locked to 5 mg with no option to uptitrate.

Renal and Hepatic Considerations

Renal impairment. No dose adjustment is required at any level of kidney function, including dialysis-dependent patients. Less than 1% of lemborexant is excreted unchanged in urine [3]. This is a meaningful advantage in geriatric prescribing, where estimated GFR below 60 mL/min/1.73 m² is present in roughly one-third of adults over 70 [10].

Hepatic impairment. Mild impairment (Child-Pugh A): no adjustment. Moderate impairment (Child-Pugh B): maximum 5 mg. Severe impairment (Child-Pugh C): avoid use entirely. Lemborexant AUC increased by approximately 50% in subjects with moderate hepatic impairment [3]. Since fatty liver disease and age-related reductions in hepatic blood flow are common in older adults, liver function should be assessed clinically before prescribing.

Deprescribing Benzodiazepines and Z-Drugs: Transitioning to Lemborexant

Many geriatric patients presenting for insomnia management are already taking a benzodiazepine or Z-drug. The 2023 AGS Beers Criteria and the Canadian Deprescribing Network both recommend tapering these agents in older adults when clinically feasible [7]. Lemborexant can serve as a bridge or replacement during this process.

No randomized trial has directly studied the protocol of tapering a benzodiazepine while simultaneously initiating lemborexant. In practice, geriatric psychiatrists and sleep specialists often use a cross-taper: reduce the benzodiazepine or Z-drug by 25% every one to two weeks while starting lemborexant 5 mg on the night of the first reduction. The patient should be monitored for rebound insomnia during the taper, which is an expected withdrawal phenomenon from GABAergic agents and should not be attributed to lemborexant failure.

A 2023 retrospective cohort study in Journal of Clinical Sleep Medicine found that 62% of patients aged 65 and older who started a DORA (lemborexant or suvorexant) were able to fully discontinue their prior benzodiazepine receptor agonist within 12 weeks [11]. The mean time to complete discontinuation was 7.3 weeks.

Practical Prescribing Checklist for Adults 65+

Before writing a lemborexant prescription for a patient 65 or older, confirm these five items:

1. CBT-I trial. The American Academy of Sleep Medicine recommends CBT-I as first-line treatment for chronic insomnia across all age groups [12]. If CBT-I has not been attempted or is unavailable, document the reason.

2. Medication reconciliation for CYP3A4 interactions. Flag diltiazem, verapamil, fluconazole, and macrolide antibiotics. If a moderate inhibitor is present, the ceiling is 5 mg.

3. Hepatic function assessment. A clinical history and basic liver panel (ALT, AST, albumin, bilirubin) are sufficient for most patients. Formal Child-Pugh scoring is reserved for known liver disease.

4. Fall risk screen. Use the Timed Up and Go (TUG) test or the STEADI algorithm from the CDC [13]. A TUG time exceeding 12 seconds warrants caution with any sedative-hypnotic.

5. Sleep environment and timing. The patient must have at least seven hours of intended sleep time remaining. Patients who routinely sleep fewer than six hours are poor candidates for any prescription hypnotic.

Start at 5 mg. Reassess at two to four weeks. If sleep onset and maintenance remain inadequate and no CYP3A4 inhibitor caps the dose, increase to 10 mg. Reassess again at four to eight weeks, and at every subsequent visit, consider whether continued pharmacotherapy is necessary.

Comparing Lemborexant to Other Geriatric Insomnia Options

The three most commonly prescribed insomnia medications in adults 65 and older are zolpidem (and its extended-release formulation), suvorexant (Belsomra), and trazodone (off-label). Each carries distinct geriatric trade-offs.

Zolpidem ER 6.25 mg is FDA-approved at a reduced geriatric dose. It is a positive allosteric modulator of GABA-A receptors. The FDA added a boxed warning in 2019 for complex sleep behaviors (sleepwalking, sleep-driving) [14]. Next-morning impairment is documented, and the FDA recommends against driving the morning after taking the extended-release formulation.

Suvorexant (Belsomra) is a fellow DORA approved at 10 mg or 20 mg. The FDA label does not require geriatric dose adjustment. Head-to-head data comparing suvorexant and lemborexant are limited to indirect comparisons, though lemborexant's higher orexin-2 receptor selectivity is hypothesized to produce a more favorable wake-to-sleep transition [15].

Trazodone 25 to 50 mg is widely used off-label for geriatric insomnia despite no FDA approval for this indication. It carries orthostatic hypotension risk, which is particularly dangerous in older adults. No polysomnographic trial in geriatric populations has demonstrated trazodone's efficacy for objective sleep measures at the low doses commonly prescribed.

Lemborexant's profile (no anticholinergic activity, no respiratory depression, no renal dose adjustment, preserved next-morning function at approved doses) positions it as a preferred pharmacologic option when CBT-I alone is insufficient.

When to Avoid Lemborexant in Older Adults

Three clinical scenarios warrant choosing a different approach. Narcolepsy or known orexin deficiency: blocking an already-deficient orexin system could worsen daytime cataplexy. Severe hepatic impairment (Child-Pugh C): drug accumulation is unpredictable. Concurrent use of a strong CYP3A4 inhibitor that cannot be discontinued: the interaction is contraindicated per the FDA label [3]. In any of these cases, non-pharmacologic strategies and alternative medication classes should be discussed with the patient and their care team.

The recommended starting dose for adults 65 and older is 5 mg orally at bedtime, with reassessment at two to four weeks and escalation to 10 mg only after confirming no CYP3A4 interaction limits the dose ceiling [3].